Table 4 Association of main baseline characteristics of RA patients with rapid radiographic progression at 2 years (univariate analysis)

Age

51.5 ± 10.7

48.2 ± 11.8

0.059

1.03 (0.99–1.05)

51.8 ± 8.9

48.4 ± 11.8

0.108

1.03 (0.99–1.06)

49.4 ± 11.4

48.4 ± 11.7

0.471

1.01 (0.98–1.03)

Female (%)

84.6

81.1

0.543

0.78 (0.35–1.74)

87.5

81.0

0.367

1.64 (0.56–4.83)

83.5

80.9

0.571

1.19 (0.65–2.20)

BMI

25.9 ± 4.9

25.3 ± 4.6

0.245

1.04 (0.98–1.10)

25.1 ± 4.9

25.3 ± 4.6

0.866

0.99 (0.927–1.08)

25.6 ± 4.7

25.2 ± 4.6

0.447

1.02 (0.97–1.07)

RF (%)

69.2

48.2

0.005

2.42 (1.29–4.53)

78.1

41.7

0.005

3.14 (1.37–7.18)

64.9

46.3

0.002

2.15 (1.33–3.47)

ACPA (%)

65.4

41.5

0.001

2.67 (1.45–4.92)

75.0

48.9

0.005

5.0 (2.106–11.872)

59.8

39.6

0.001

2.271 (1.418–3.635)

Total mSharp score

4.0 ± 4.8

3.7 ± 4.4

0.644

1.10 (0.95–1.08)

4.5 ± 5.0

3.7 ± 4.4

0.341

1.04 (0.96–1.12)

3.8 ± 4.8

3.7 ± 4.3

0.837

1.01 (0.95–1.06)

DAS28(ESR)-4v

5.5 ± 1.4

5.3 ± 1.1

0.211

1.2 (0.9–1.5)

5.5 ± 1.5

5.3 ± 1.2

0.331

1.16 (0.86–1.59)

5.3 ± 1.3

5.3 ± 1.1

0.784

1.03 (0.84–1.25)

logCRP level

1.25 ± 0.51

0.98 ± 0.46

0.000

3.3 (1.8–6.3)

1.25 ± 0.49

1.00 ± 0.47

0.004

1.01 (1.00–1.02)

1.16 ± 0.47

0.96 ± 0.46

0.001

2.414(1.445–4.03)

ESR

35 ± 26

28 ± 24

0.009

1.01 (1.00–1.02)

36 ± 29

28 ± 24

0.016

1.01 (1.00–1.02)

32 ± 25

26 ± 21

0.030

1.01 (1.00–1.02)

Steroid use (%)

19.2

13.4

0.264

0.651 (0.305–1.390)

8.0

13.4

0.413

1.66 (0.49–5.65)

83.5

86.6

0.455

0.785 (0.416–1.483)

cDMARD use (%)

89.6

82.2

0.210

1.86 (0.71–4.91)

85.2

83

0.774

1.18 (0.39–3.53)

90.2

80.8

0.041

2.19 (1.03–4.64)

logOPG/TRAIL ratio Q <25 (%)

23.5

25.6

0.894 (0.447–1.787)^a

12.9

26.4

0.412 (0.140–1.210)^a

26.0

25.1

1.051 (0.619–1.785)^a

LogGPG/TRAIL ratio Q25–75 (%)

47.1

50.6

0.685

45.2

50.6

0.041

53.1

49.1

0.614

logOPG/TRAIL ratio Q >75 (%)

29.4

23.8

1.335 (0.695–2.568)^b

41.9

23.0

2.419 (1.136–5.152)^b*

20.8

25.8

0.757 (0.432–1.325)^b